-
Assessing the turn over time of critical value in hospitals
Mohan CK, Sugathan NV and Chandraja CV
Opinion Article: Clinical Investigation
-
Assessing the turn over time of critical value in hospitals
Mohan CK, Sugathan NV and Chandraja CV
Opinion Article: Clinical Investigation
-
Assessing the turn over time of critical value in hospitals
Mohan CK, Sugathan NV and Chandraja CV
Opinion Article: Clinical Investigation
-
Assessing the turn over time of critical value in hospitals
Mohan CK, Sugathan NV and Chandraja CV
Opinion Article: Clinical Investigation
-
Assessing the turn over time of critical value in hospitals
Mohan CK, Sugathan NV and Chandraja CV
Opinion Article: Clinical Investigation
-
Assessing the turn over time of critical value in hospitals
Mohan CK, Sugathan NV and Chandraja CV
Opinion Article: Clinical Investigation
-
Assessing the turn over time of critical value in hospitals
Mohan CK, Sugathan NV and Chandraja CV
Opinion Article: Clinical Investigation
-
Assessing the turn over time of critical value in hospitals
Mohan CK, Sugathan NV and Chandraja CV
Opinion Article: Clinical Investigation
-
Utilizing interim Phase II results to streamline Phase III development: what does the future hold?
Jie Huang
Editorial: Clinical Investigation
-
Utilizing interim Phase II results to streamline Phase III development: what does the future hold?
Jie Huang
Editorial: Clinical Investigation
-
Utilizing interim Phase II results to streamline Phase III development: what does the future hold?
Jie Huang
Editorial: Clinical Investigation
-
Utilizing interim Phase II results to streamline Phase III development: what does the future hold?
Jie Huang
Editorial: Clinical Investigation
-
Utilizing interim Phase II results to streamline Phase III development: what does the future hold?
Jie Huang
Editorial: Clinical Investigation
-
Utilizing interim Phase II results to streamline Phase III development: what does the future hold?
Jie Huang
Editorial: Clinical Investigation
-
Utilizing interim Phase II results to streamline Phase III development: what does the future hold?
Jie Huang
Editorial: Clinical Investigation
-
Utilizing interim Phase II results to streamline Phase III development: what does the future hold?
Jie Huang
Editorial: Clinical Investigation
-
What should be the primary end point in irritable bowel syndrome?
Allen W Mangel
Clinical Trail Prospective: Clinical Investigation
-
What should be the primary end point in irritable bowel syndrome?
Allen W Mangel
Clinical Trail Prospective: Clinical Investigation
-
What should be the primary end point in irritable bowel syndrome?
Allen W Mangel
Clinical Trail Prospective: Clinical Investigation
-
What should be the primary end point in irritable bowel syndrome?
Allen W Mangel
Clinical Trail Prospective: Clinical Investigation
-
What should be the primary end point in irritable bowel syndrome?
Allen W Mangel
Clinical Trail Prospective: Clinical Investigation
-
What should be the primary end point in irritable bowel syndrome?
Allen W Mangel
Clinical Trail Prospective: Clinical Investigation
-
What should be the primary end point in irritable bowel syndrome?
Allen W Mangel
Clinical Trail Prospective: Clinical Investigation
-
What should be the primary end point in irritable bowel syndrome?
Allen W Mangel
Clinical Trail Prospective: Clinical Investigation
-
Immunotherapy & cancer - making the past prologue Immunotherapeutic combinations for cancer
Susan F Slovin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Immunotherapy & cancer - making the past prologue Immunotherapeutic combinations for cancer
Susan F Slovin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Immunotherapy & cancer - making the past prologue Immunotherapeutic combinations for cancer
Susan F Slovin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Immunotherapy & cancer - making the past prologue Immunotherapeutic combinations for cancer
Susan F Slovin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Immunotherapy & cancer - making the past prologue Immunotherapeutic combinations for cancer
Susan F Slovin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Immunotherapy & cancer - making the past prologue Immunotherapeutic combinations for cancer
Susan F Slovin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Immunotherapy & cancer - making the past prologue Immunotherapeutic combinations for cancer
Susan F Slovin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Immunotherapy & cancer - making the past prologue Immunotherapeutic combinations for cancer
Susan F Slovin
Review: Clinical Trail Outcomes: Clinical Investigation
-
HCV protease inhibitors: using the evidence to guide clinical practice
Derek Yu, Jordan J Feld
Review: Clinical Trail Outcomes: Clinical Investigation
-
HCV protease inhibitors: using the evidence to guide clinical practice
Derek Yu, Jordan J Feld
Review: Clinical Trail Outcomes: Clinical Investigation
-
HCV protease inhibitors: using the evidence to guide clinical practice
Derek Yu, Jordan J Feld
Review: Clinical Trail Outcomes: Clinical Investigation
-
HCV protease inhibitors: using the evidence to guide clinical practice
Derek Yu, Jordan J Feld
Review: Clinical Trail Outcomes: Clinical Investigation
-
HCV protease inhibitors: using the evidence to guide clinical practice
Derek Yu, Jordan J Feld
Review: Clinical Trail Outcomes: Clinical Investigation
-
HCV protease inhibitors: using the evidence to guide clinical practice
Derek Yu, Jordan J Feld
Review: Clinical Trail Outcomes: Clinical Investigation
-
HCV protease inhibitors: using the evidence to guide clinical practice
Derek Yu, Jordan J Feld
Review: Clinical Trail Outcomes: Clinical Investigation
-
HCV protease inhibitors: using the evidence to guide clinical practice
Derek Yu, Jordan J Feld
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Hepatitis B needle-free vaccines: a step closer
Olga Borges, Gerrit Borchard
Editorial: Clinical Investigation
-
Hepatitis B needle-free vaccines: a step closer
Olga Borges, Gerrit Borchard
Editorial: Clinical Investigation
-
Hepatitis B needle-free vaccines: a step closer
Olga Borges, Gerrit Borchard
Editorial: Clinical Investigation
-
Hepatitis B needle-free vaccines: a step closer
Olga Borges, Gerrit Borchard
Editorial: Clinical Investigation
-
Hepatitis B needle-free vaccines: a step closer
Olga Borges, Gerrit Borchard
Editorial: Clinical Investigation
-
Hepatitis B needle-free vaccines: a step closer
Olga Borges, Gerrit Borchard
Editorial: Clinical Investigation
-
Hepatitis B needle-free vaccines: a step closer
Olga Borges, Gerrit Borchard
Editorial: Clinical Investigation
-
Hepatitis B needle-free vaccines: a step closer
Olga Borges, Gerrit Borchard
Editorial: Clinical Investigation